24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Richard Francis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:10
"To build Israeli companies like Anduril or Palantir, we must focus on comprehensive solutions, not niche ones"
11:25
"Companies that fail to adapt their DNA to AI will be left behind"
09:52
CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move
09:18
‘I sent out dozens of resumes’: The brutal job market facing tech graduates
More stories
Buzz
Most popular
Daily
Weekly
1
Intel in talks to sell chip manufacturing to TSMC
2
Broadcom eyes Intel’s chip design unit as TSMC considers its factories
3
Intel’s existential crisis: Can Broadcom, TSMC, and Trump save the troubled chip giant?
4
How Intel ruined an Israeli startup it bought for $2B—and lost the AI race
5
Is Intel’s time up? TSMC and Broadcom move in as the chipmaker falters
More news
Richard Francis
3 stories about Richard Francis
Teva surpasses expectations in Q4 but sets cautious outlook for 2025
29.01.25
|
Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
Teva soars with double-digit growth in Q3, raises annual forecast
06.11.24
|
Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
Teva CEO: "The company played not to lose, now we’ll play to win"
21.02.24
|
Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory